Correlation of Serum and Synovial Osteocalcin, Osteoprotegerin and Tumor Necrosis Factor-Alpha with the Disease Severity Score in Knee Osteoarthritis

Csifo, Enikő; Katona, Tímea; Arseni, Juliánna; Nagy, E; Gergely, I; Nagy, Orsolya

doi:10.2478/amma-2014-0021

Cited by 6 publications

(4 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…OPG was measured in serum and synovial fluid of patients with primary knee osteoarthritis was found higher in synovial fluid and also was associated with disease activity (19). Similar results were found by other authors too (20).…”

Section: Discussionsupporting

confidence: 78%

Synovial and serum levels of osteocalcin, osteoprotegerin and β-crosslaps in patients with calcium pyrophosphate deposition disease

Vele¹,

Silaghi²,

Damian³

et al. 2019

Ro J Rheumatol.

View full text Add to dashboard Cite

Background. Calcium pyrophosphate deposition disease is defined by deposition of calcium pyrophosphate crystals in hyaline cartilage, fibrocartilage and soft tissues. The study of bone markers is of great interest in different types of arthritis. In patients with calcium pyrophosphate deposition disease, bone turnover markers may yield additional information from many perspectives. Objectives. To measure synovial and serum levels of osteocalcin, osteoprotegerin and β-CrossLaps in patients with calcium pyrophosphate deposition disease. Material and methods. In this pilot, prospective study were enrolled eight patients with calcium pyrophosphate deposition disease. Osteocalcin, osteoprotegerin and β-CrossLaps were measured in serum and in the synovial fluid using ELISA kits. Results. Synovial fluid osteocalcin was significantly lower comparative with serum osteocalcin (2.1±0.6 versus 9.21 ±46, p=0.02). Synovial fluid osteoprotegerin was significantly higher than serum osteoprotegerin (55.5±284 versus 8.44±7; p=0.0001). Synovial fluid β-CrossLaps wasn't statistically different from serum levels (6146±66818 versus 6077±12212; p=0.5). Ratios between synovial fluid and serum levels were 0.22 for osteocalcin, 6.57 for osteoprotegerin and 1.01 for β-CrossLaps. Conclusions. Osteocalcin was higher in serum than in the synovial fluid. β-CrossLaps had similar values in serum and synovial fluid. Osteoprotegerin was higher in synovial fluid than serum.

show abstract

Section: Discussionsupporting

confidence: 78%

Synovial and serum levels of osteocalcin, osteoprotegerin and β-crosslaps in patients with calcium pyrophosphate deposition disease

Vele¹,

Silaghi²,

Damian³

et al. 2019

Ro J Rheumatol.

View full text Add to dashboard Cite

show abstract

“…Обнаруженное нами более выраженное, по сравнению с КГ, снижение уровня таких лабораторных показателей крови, как СРБ, ФНО-α и ИЛ-6, лептин, адипсин, PIIANP, CTX-1, ММП-3 и ММП-13, COMP, склеростин при существенном увеличении уровня остеокальцина и 25(ОН) D 3 в крови пациентов всех фенотипов ОА КС в ОГ свидетельствует об интенсификации следующих молекулярных процессов в клетках суставных тканей: устранение тормозящего влияния склеростина на Wnt/β-катенин-сигнальную систему со снижением концентрации β-катенина в цитоплазме и ядре остеобласта и усилением пролиферации и дифференцировки остеобластов [30], стабилизация процессов костного ремоделирования с предотвращением дестабилизации хрящевой ткани со стороны субхондральной кости (СТХ-1, PIIANP, остеокальцин) [31], увеличение обмена коллагена I типа в костной ткани с активацией механизмов ремоделирования костной ткани у больных ОА в оперированном и контралатеральном КС [32][33][34], увеличение уровня синтеза коллагена II типа в хряще при ОА контралатерального КС (PIIANP), что соответствует данным других авторов [35], снижение степени системного и локального воспаления (синовит), ограничение деградации ЭЦМ и стабилизация уровня катаболических факторов в хрящевой ткани (СРБ, ГК, лептин, адипсин, ФНО-α, ММП-3) с замедлением темпов деградации хрящевой ткани в контралатеральном суставе [36][37][38], ограничение пато-логического распада коллагена II типа и аггрекана в хрящевой ткани контралатерального сустава, а также процессов дегенерации в субхондральной кости в обоих КС (ММП-13) [39,40], уменьшение выраженности болевого синдрома (ИЛ-6, COMP) [41]. Выраженность динамики содержания биомаркеров ключевых патологических процессов и регулируемых ими патобиохимических процессов различалась в подгруппах пациентов с разными фенотипами ОА КС, принимавших ХС в парентеральной форме до ТЭКС в предоперационном периоде: наиболее выраженное снижение уровня СРБ, ФНО-α, ИЛ-6, COMP (противовоспалительный и обезболивающий эффекты ХС) отмечено у пациентов с воспалительным фенотипом, уровня адипсина и лептина (противовоспалительный и метаболический эффекты ХС) -у пациентов с эндокринным фенотипом, концентрации ММП-13 -у пациентов с эндокринным и посттравматическим фенотипами (структурно/болезньмодифицирующий эффект), концентрации склеростина, СТХ-1, PIIANP, ММП-3 при более значимом увеличении уровня остеокальцина (структурно/болезньмодифицирующий эффект) -у пациентов с посттравматическим фенотипом; различия в увеличении уровня 25(ОН)D 3 (структурно/ болезньмодифицирующий эффект) получены в подгруппах посттравматического и эндокринного фенотипов ОА КС.…”

Section: Discussionunclassified

Stratification of decompensated osteoarthritis and modern options of the preoperative therapy using Chondroguard® based on pheno- and endotyping

Минасов¹,

Лила²,

Nazarenko³

et al. 2023

Russian Medical Inquiry

View full text Add to dashboard Cite

Aim: to perform a retrospective analysis of the pattern of changes in the structural and functional characteristics of articular cartilage and biomarkers in the blood serum of patients with knee osteoarthritis (OA), Kellgren-Lawrence Grade 3, and Grade 2 joint dysfunction, taking into consideration the identified phenotypes and endotypes of knee OA during the parenteral treatment with highly purified chondroitin sulfate (CS, Chondroguard®). Patients and Methods: the authors performed a retrospective analysis of the results of the earlier stage of an open prospective controlled randomized study, which included 67 patients with knee OA. The patients were referred to total knee arthroplasty (TKA). All patients received NSAIDs in a standard daily dose. At the stage of open prospective randomized clinical study, the patients were split into the control group (CG, n=35) and the study group (SG, n=32). In addition to NSAIDs, the SG patients received a course of parenteral CS two months prior to TKA. Retrospectively, patients in the SG and CG were divided into subgroups according to three disease phenotypes: an inflammatory phenotype caused by synovitis (CG: n=13; SG: n=11); injury-related phenotype (joint injury in the medical history) (CG: n=10; SG: n=10), and endocrine phenotype (CG: n=12; SG: n=11). Based on the identified phenotypes, the biosamples of the subchondral bone, articular cartilage of the femur and tibia, and the articular capsule obtained during TKA surgery procedure were assessed. Also, the levels of hyaluronic acid, ultrasensitive CRP, TNF-α, IL-6, leptin, adipsin, PIIANP, CTX-1, osteocalcin, MMP-3 and -13, COMP, sclerostin, 25(OH)D3 were determined in the blood at the baseline (visit 0), release from the hospital (visit 1) and 3 months after TKA (visit 3). Results: the morphological analysis of joint tissues and the laboratory blood tests provided a basis for characterizing at the endotype level the following three clinical and pathogenetic knee OA phenotypes: inflammatory, posttraumatic and endocrine. In patients with distinct phenotypes of knee OA, differences were revealed in the intensification of adaptive structural modifications in all layers of the articular cartilage and the extent of inflammation restriction in the synovial membrane of the knee joint, as well as the degradation manifestations in the subchondral bone after a two-month preoperative treatment course with Chondroguard ®. A more pronounced and considerable decrease in the blood levels of all tested compounds along with a significant increase in the blood levels of osteocalcin and 25(OH)D 3 were reported in patients with all phenotypes of knee OA in SG as compared to the changes in the lab tests detected in patients with all phenotypes of knee OA in CG. Conclusion: the extent of CS anti-inflammatory, analgetic, metabolic and structure-modifying effects may depend on endotypes determined in patients with specific OA phenotypes. These findings may pave the way for personalized Chondroguard® therapy to be used in patients with OA of various locations, stages, and degrees of functional impairment by identifying their specific OA phenotypes and endotypes. KEYWORDS: osteoarthritis, phenotype, endotype, biomarkers, hyaline cartilage, synovial membrane, morphology, chondroitin sulfate, Chondroguard, arthroplasty. FOR CITATION: Minasov T.B., Lila A.M., Nazarenko A.G. et al. Stratification of decompensated osteoarthritis and modern options of the preoperative therapy using Chondroguard® based on pheno- and endotyping. Russian Medical Inquiry. 2023;7(3):124–136 (in Russ.). DOI: 10.32364/2587-6821-2023-7-3-124-136.

show abstract

“…Alongside with it OC has calcium binding effect and takes part in the bone mineralization [17]. The series of researches demonstrated the increase of OC level in patients with OA on the background of intensification of remodeling processes and changes in the process of bone tissue mineralization that was associated with further osteophytosis progressing [19,20]. Thus, OC can be considered as the specific marker of functional activity of SCB osteoblasts and the sensitive marker of the bone tissue remodeling.…”

Section: Introductionmentioning

confidence: 99%

The Markers of Bone Metabolism and System Inflammation in Patients With Osteoarthritis Depending on Body Mass, the Influence of Symptomatic Slow Acting Drugs

Черкасова

Kuryata

2016

EUREKA: Health Sciences

View full text Add to dashboard Cite

Aim. To assess the levels of markers of the bone synthesis and system inflammation in patients with osteoarthritis (OA) in combination with obesity and their dynamic under the influence of basic treatment. Materials and methods. The research included 40 women with OA, 46–78 years old (mean age – 59,8±1,5 years). Duration of the disease varied from 3 to 36 years (mean duration – 10,0±1,1 years). Mean body mass index (BMI) among patients was 30,6±0,7 [22,3; 39,5]kg/m2, according to which patients were divided in 3 groups: patients with OA without obesity (n=17), patients with OA with 1 degree of obesity (n=14), patients with OA with 2 degree of obesity (n=9). The level of osteochondral metabolism was assessed using quantitative measuring of the levels of procollagen IC-terminal propeptide (РІСР), (Cloud-CloneCorp. “procollagen IC-Terminal Propeptide”, USA) and osteocalcin (Roche Diagnostics «N-MID Osteocalcin», Switzerland) on analyzer «ELECSYS 2010» by the method of immune-enzyme analysis; the level of the system inflammation was assessed by the level of C-reactive protein (CRP) by the method of immunoturbidimetry. The clinical efficacy was assessed by the dynamics of intensity levels of pain syndromes at physical load and at rest by the visual-analogue scale (VAS). The measuring of РІСР, osteocalcin and CRP levels and also the assessment of clinical efficacy as to the decrease of pain syndrome were carried out twice – at the beginning and at the end of observation. The period of observation is 2 months. Results. The presence of direct correlation between РІСР and BMI (r=0,62; р=0,008) among patients with OA in combination with the normal body weight was established at the research, whereas among patients with OA in combination with obesity the analogous correlation was demonstrated between SRP and BMI (r=0,43; р=0,04) on the background of correlation of PICP and OC levels (r=0,46; р=0,03). Obesity in patients with OA was associated with the reliably higher levels of pain at both rest and physical load from the side of knee joints, with maximal intensity of the pain syndrome among patients with OA and 1 degree of obesity. Statistical analysis did not reveal the reliable dependence of РІСР and OC in patients with OA from the initial CRP level on the background of tendency to the higher РІСР level and lower OC level among patients with initially increased CRP level comparing with ones with normal CRP level. The therapy with basic preparations at OA during 2 months among patients with OA with increased CRP level led to the reliable decrease of РІСР level (р=0,0076) and the tendency to increase of OC level (р˃0,05), without the reliably significant difference between the initial and final РІСР and OC levels among patients with OA and normal CRP level. At the end of observation period the maximal analgesic effect was demonstrated as to the articulate pain at rest from the side of knee joints (р˂0,001) among patients with OA, who received diacerein, with clinically comparable effect from the side of other aticulate zones (р˂0,05), that was associated with reliable decrease of CRP level (р=0,013). Discussion. The received results testify that the control of the system inflammation level at OA is a target not only relative to the decrease of pain syndrome but also conditions the stable state of subchondral bone (SCB), providing the compensation of processes of destruction and synthesis in bone tissue. The significance of procollagen IC-terminal propeptide (РІСР) and osteocalcin (OC) as the markers of bone synthesis that are able to reflect metabolic processes in SCB at OA, and also the discordant influence of CRP level on PICP level at the relative stability of OC level were demonstrated at the research. The received results allow consider the inflammatory process at OA as a target for preservance of the bone tissue, conditioning the expedience of taking into account the ability of OA basic preparations to realize the control influence on the level of system inflammation. Diacerein that in ESCEO recommendations (2014) is related to the preparations of the 1 step of treatment of patients with OA provides the control on inflammation and stability of osteocalcin level that testifies to the balance of catabolic processes in SCB. Conclusions. At OA the levels of procollagen IC-terminal propeptide (РІСР) and osteocalcin (OC) were not associated with obesity and did not depend on the initial CRP level at the presence of correlation between РІСР level and BMI among patients with OA with the normal body weight and BMI and CRP level among patients with OA in combination with obesity. The absence of reliable dynamics from РІСР side and maintenance of the stable OC level on the background of the reliable anti-inflammatory effect at using diacerein in patients with OA can testify to the compensatory adequacy of reparation processes in SCB.

show abstract

Correlation of Serum and Synovial Osteocalcin, Osteoprotegerin and Tumor Necrosis Factor-Alpha with the Disease Severity Score in Knee Osteoarthritis

Cited by 6 publications

References 13 publications

Synovial and serum levels of osteocalcin, osteoprotegerin and β-crosslaps in patients with calcium pyrophosphate deposition disease

Synovial and serum levels of osteocalcin, osteoprotegerin and β-crosslaps in patients with calcium pyrophosphate deposition disease

Stratification of decompensated osteoarthritis and modern options of the preoperative therapy using Chondroguard® based on pheno- and endotyping

The Markers of Bone Metabolism and System Inflammation in Patients With Osteoarthritis Depending on Body Mass, the Influence of Symptomatic Slow Acting Drugs

Contact Info

Product

Resources

About